As­traZeneca keeps the ball rolling on Dai­ichi-part­nered En­her­tu, pick­ing up 2nd in­di­ca­tion in gas­tric can­cer

As­traZeneca’s big gam­ble on Dai­ichi Sankyo’s an­ti­body-drug con­ju­gate En­her­tu has al­ready paid off with a big ap­proval in breast can­cer more than a year ago. But the part­ners have big plans for their block­buster in the mak­ing, and a new nod in gas­tric can­cer will raise their spir­its even high­er.

The FDA on Fri­day ap­proved En­her­tu to treat lo­cal­ly ad­vanced or metasta­t­ic HER2-pos­i­tive gas­tric or gas­troe­sophageal junc­tion ade­no­car­ci­no­ma in pa­tients who have pre­vi­ous­ly un­der­gone at least one round of treat­ment with a Her­ceptin-based reg­i­men, As­traZeneca said in a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER